Ann: Phase II Preliminary Results, page-22

"MELBOURNE, AUSTRALIA (24 June 2022): Hexima Limited (ASX:HXL) announces that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete".

So what would you have the announcement say ? .........We are very sorry it was all crap - but we had fun whilst it lasted ? & we hereby tender out resignation.

Things happen - thats the nature of R & D - meanwhile I expect we will hear more .
Meanwhile HXL has always been a very thinly traded stock . Looks like a few larger holders wanted to exit ASAP , maybe
to take the write off for this FYE ? Who Knows . Market sentiment is fragile . Lots of holders have likely large profits taken on Biotec & other sectors etc .

Maybe you should read more about the IP

Keep an open mind !!
Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete".

Meanwhile the IP they are exploring has the likelihood of multiple high value applications .

Lets see what transpires over the next couple of months , before throwing the baby out with the bath water .